Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers Paris, France, and Houston, Texas, ...

ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies Pooled results from the BOREAS and NOTUS studies show meaningful clinical benefit ...

Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients ...

The phenomenon of smoldering-associated worsening in multiple sclerosis has been widely accepted by the medical community, yet much work is needed to fully integrate it into clinical practice.

Hemophilia can affect nearly every aspect of a person’s life, but these daily impacts are often overlooked, and current solutions rarely go beyond medical care. Sanofi is committed to working with the ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

At Sanofi, we’re proud to be premium partner of Paris 2024. Like Olympians and Paralympians, we spend every day challenging ourselves and each other to be better, go further, and to never, ever settle ...

Please complete this form to contact Sanofi Canada. All information you provide will be maintained in accordance with our privacy policy. We provide product information and cannot offer medical advice ...